Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Nanomedical Theranostics in Cardiovascular Disease.

Tang J, Lobatto ME, Read JC, Mieszawska AJ, Fayad ZA, Mulder WJ.

Curr Cardiovasc Imaging Rep. 2012 Feb;5(1):19-25. Epub 2011 Nov 29.

2.

Image-guided nanosystems for targeted delivery in cancer therapy.

Iyer AK, He J, Amiji MM.

Curr Med Chem. 2012;19(19):3230-40. Review.

PMID:
22612697
3.

Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy.

Li X, Kim J, Yoon J, Chen X.

Adv Mater. 2017 Jun;29(23). doi: 10.1002/adma.201606857. Epub 2017 Mar 29. Review.

PMID:
28370546
4.

Application of Theranostics in Oncology.

Lymperopoulos G, Lymperopoulos P, Alikari V, Dafogianni C, Zyga S, Margari N.

Adv Exp Med Biol. 2017;989:119-128. doi: 10.1007/978-3-319-57348-9_10.

PMID:
28971421
5.

Nanotechnology: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2006;6(19):1-43. Epub 2006 Nov 1.

6.

Will nanotechnology influence targeted cancer therapy?

Grimm J, Scheinberg DA.

Semin Radiat Oncol. 2011 Apr;21(2):80-7. doi: 10.1016/j.semradonc.2010.10.003. Review.

7.

Nanotechnology and atherosclerosis imaging: emerging diagnostic and therapeutic applications.

Schoenhagen P, Conyers JL.

Recent Pat Cardiovasc Drug Discov. 2008 Jun;3(2):98-104. Review.

PMID:
18537760
8.

Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).

Formentini I, Bobadilla M, Haefliger C, Hartmann G, Loghman-Adham M, Mizrahi J, Pomposiello S, Prunotto M, Meier M.

Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii81-8. doi: 10.1093/ndt/gfs270. Epub 2012 Jun 25.

PMID:
22734108
9.

Integrated preclinical cardiovascular prevention: a new paradigm to face growing challenges of cardiovascular disease.

Volpe M, Mastromarino V, Battistoni A.

Am J Cardiovasc Drugs. 2015 Jun;15(3):163-70. doi: 10.1007/s40256-015-0114-7. Review.

PMID:
25894618
10.

Nanomedicine for Atherosclerosis: Molecular Imaging and Treatment.

Karagkiozaki V, Logothetidis S, Pappa AM.

J Biomed Nanotechnol. 2015 Feb;11(2):191-210. Review.

PMID:
26349296
11.

Responsible healthcare innovation: anticipatory governance of nanodiagnostics for theranostics medicine.

Fisher E, Boenink M, van der Burg S, Woodbury N.

Expert Rev Mol Diagn. 2012 Nov;12(8):857-70. doi: 10.1586/erm.12.125. Review.

PMID:
23249203
12.

Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases.

Sharma PA, Maheshwari R, Tekade M, Tekade RK.

Curr Pharm Des. 2015;21(30):4465-78. Review.

PMID:
26354926
13.

Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers.

Caldorera-Moore ME, Liechty WB, Peppas NA.

Acc Chem Res. 2011 Oct 18;44(10):1061-70. doi: 10.1021/ar2001777. Epub 2011 Sep 20. Review.

14.

Self-assembled glycol chitosan nanoparticles for disease-specific theranostics.

Yhee JY, Son S, Kim SH, Park K, Choi K, Kwon IC.

J Control Release. 2014 Nov 10;193:202-13. doi: 10.1016/j.jconrel.2014.05.009. Epub 2014 May 17. Review.

PMID:
24845129
15.

Theranostics for cancer therapy.

Palekar-Shanbhag P, Jog SV, Chogale MM, Gaikwad SS.

Curr Drug Deliv. 2013 Jun;10(3):357-62. Review.

PMID:
23286214
16.

Perspectives and potential applications of nanomedicine in breast and prostate cancer.

Liu Y, Solomon M, Achilefu S.

Med Res Rev. 2013 Jan;33(1):3-32. doi: 10.1002/med.20233. Epub 2010 Nov 9. Review.

PMID:
23239045
17.

Theranostic magnetic nanoparticles.

Yoo D, Lee JH, Shin TH, Cheon J.

Acc Chem Res. 2011 Oct 18;44(10):863-74. doi: 10.1021/ar200085c. Epub 2011 Aug 8. Review. Erratum in: Acc Chem Res. 2012 Sep 18;45(9):1622.

PMID:
21823593
18.

Requisites for successful theranostics with radionuclide-based reporter gene imaging.

Ahn BC.

J Drug Target. 2014 May;22(4):295-303. doi: 10.3109/1061186X.2013.878940. Epub 2014 Jan 13. Review.

PMID:
24417717
19.

Cardiovascular health informatics: risk screening and intervention.

Hartley CJ, Naghavi M, Parodi O, Pattichis CS, Poon CC, Zhang YT.

IEEE Trans Inf Technol Biomed. 2012 Sep;16(5):791-4.

20.

Theranostics in primary care: pharmacogenomics tests and beyond.

Bartlett G, Antoun J, Zgheib NK.

Expert Rev Mol Diagn. 2012 Nov;12(8):841-55. doi: 10.1586/erm.12.115. Review.

PMID:
23249202

Supplemental Content

Support Center